Xeris files KEVEYIS patent suits and Xeris Biopharma Holdings stock trades at EUR 8.60

Published on 10/15/2026 at 13:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xeris filed two KEVEYIS patent suits on October 13, 2026. Xeris Biopharma Holdings stock costs EUR 8.60 on October 15, 2026, with USD 1.8 billion market value.

Patent protection and commercial growth

Xeris filed two patent suits on October 13, 2026, over U.S. Patent No. 12,758,502.
Second-quarter 2026 revenue reached USD 92.00 million, with net product revenue growth of 34.00 percent.
Xeris Biopharma Holdings stock trades at EUR 8.60 at 1:03 p.m. CEST at Lang & Schwarz on October 15, 2026.

XERS, US98422E1038, Illustration mit AI erstellt.

Xeris Biopharma Holdings, Inc. (ISIN US98422E1038) filed two patent infringement lawsuits on October 13, 2026, over generic versions of KEVEYIS, according to StockTitan. The filing concerns U.S. Patent No. 12,758,502 and seeks injunctions, damages and related relief, but it does not represent a court decision.

What does the patent action protect?

The lawsuits cover generic dichlorphenamide products that Xeris says infringe the newly granted patent connected with KEVEYIS. The company is seeking a judgment of infringement and an injunction against further infringement, while the commercial value depends on the duration and scope of any protection ultimately recognized by the court.

Three dates define the setup

On August 6, 2026, Xeris reported second-quarter revenue of USD 92.00 million and net product revenue growth of 34.00 percent, according to Benzinga. On October 6, 2026, Barclays raised its price target from USD 12.00 to USD 14.00 and kept an Overweight rating, as reported by Markets Insider. The October 13, 2026 patent filing is the latest event.

The operating figures provide a counterweight to the legal uncertainty. Recorlev net revenue rose 81.00 percent year over year to nearly USD 57.00 million in the second quarter of 2026, while Xeris raised the lower end of its full-year 2026 revenue guidance to USD 385.00 million from USD 380.00 million, according to Benzinga. The guidance range is USD 385.00 million to USD 390.00 million.

Stock price and valuation context

Xeris Biopharma Holdings has a market capitalization of USD 1.8 billion as of October 14, 2026. Its primary listing is on the Nasdaq Global Select Market under ticker XERS, and the company operates in the healthcare biotechnology industry.

Xeris Biopharma Holdings was trading at EUR 8.60 at Lang & Schwarz on October 15, 2026, at 1:03 p.m. CEST. The Xetra close required for a daily comparison was not available with a dated value, so no percentage change is stated. The further course of trading is shown by the continuously updated real-time quote of Xeris Biopharma stock.